In the Oct. 20 issue of Nature, researchers at the Wellcome Trust Sanger Institute and Sangamo BioSciences, reported some dramatic results in the field of stem cell therapeutics. 
News & Commentaries
The fast-paced, vibrant world of stem cell science has more than its fair share of brilliant minds. Many probably have at one time or another considered striking out on their own to market some new invention from their lab.
Human development is the work of stem cells.
On April 19, Geron Corp. presented safety data on the first patient in its groundbreaking clinical trial of GRNOPC1.
On January 3, stem cell therapeutics company Advanced Cell Technology (ACT) announced it had received approval from the US Food and Drug Administration to kick off a Phase I/II clinical trial using the company's retinal epithelial cells (RPE).
You don’t need much scaffolding for a one-story home, but if you’re putting up a high-rise, you’ll require plenty of it to create the rising edifice.
California researchers are set to begin the first clinical trial of souped-up stem cells that seek and destroy brain cancer by delivering the means to make a potent chemotherapeutic.
While many stem cell scientists are basking in the afterglow of induced pluripotency, and working on ways to de-differentiate and re-differentiate cells, a few researchers are already thinking about a shortcut.
Many stem cell biologists have experienced the frustration: you do an experiment; your lab mate at the next bench does the same. But the two of you get different results.
A 57-year-old man, suffering seizures and headaches, was diagnosed with a brain tumor in 2005. Doctors at the City of Hope cancer center in Duarte, California, removed the mass, but knew his cancer was of a type likely to return.